J. Riesmeyer

P. McCollam, J. Riesmeyer, D. A. Foster, 2003, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

Comparison of one-year outcomes. . . . ESPRIT

J. Riesmeyer, P. R. Reid, Debra L. Miller, 2003 .

Impact of Baseline Glycemic Control on Residual Cardiovascular Risk in Patients With Diabetes Mellitus and High‐Risk Vascular Disease Treated With Statin Therapy

J. S. St. John, A. Lincoff, S. Nissen, 2019, Journal of the American Heart Association.

Evacetrapib and Cardiovascular Outcomes in High‐Risk Vascular Disease

C. Granger, D. Rader, P. Barter, 2017, The New England journal of medicine.

Plasma Aldosterone Levels Are Not Associated With Cardiovascular Events Among Patients With High‐Risk Vascular Disease: Insights From the ACCELERATE Trial

A. Lincoff, S. Nissen, E. McErlean, 2019, Journal of the American Heart Association.

Evacetrapib and Cardiovascular Outcomes in High-Risk Vascular Disease

P. Barter, A. Lincoff, H. Brewer, 2017 .

Navigating the Future of Cardiovascular Drug Development—Leveraging Novel Approaches to Drive Innovation and Drug Discovery: Summary of Findings from the Novel Cardiovascular Therapeutics Conference

S. Solomon, K. Mahaffey, T. Povsic, 2017, Cardiovascular Drugs and Therapy.

Effect of CETP inhibition with evacetrapib in patients with diabetes mellitus enrolled in the ACCELERATE trial

J. S. St. John, A. Lincoff, S. Nissen, 2020, BMJ Open Diabetes Research & Care.

Safety of Abciximab Administration During PCI of Patients with Previous Stroke

D. Sane, J. Riesmeyer, R. Applegate, 2005, Journal of Thrombosis and Thrombolysis.

Comparative effects of cholesteryl ester transfer protein inhibition, statin or ezetimibe on lipid factors: The ACCENTUATE trial.

C. Ballantyne, S. Nissen, S. Nicholls, 2017, Atherosclerosis.

TRITON and Beyond: New Insights into the Profile of Prasugrel

D. Erlinge, J. Riesmeyer, J. Jakubowski, 2011, Cardiovascular therapeutics.

Impact of Regulatory Guidance on Evaluating Cardiovascular Risk of New Glucose-Lowering Therapies to Treat Type 2 Diabetes Mellitus

Neha J. Pagidipati, D. DeMets, M. Pfeffer, 2020, Circulation.

The dual glucose‐dependent insulinotropic peptide and glucagon‐like peptide‐1 receptor agonist, tirzepatide, improves lipoprotein biomarkers associated with insulin resistance and cardiovascular risk in patients with type 2 diabetes

M. Taskinen, K. Duffin, J. Riesmeyer, 2020, Diabetes, obesity & metabolism.

PCV64 INDEX, FOLLOW-UP AND TOTAL HOSPITALIZATION COSTS IN PATIENTS WITH ACUTE CORONARY SYNDROMES UNDERGOING PLANNED PERCUTANEOUS CORONARY INTERVENTION TREATED WITH PRASUGREL VS. CLOPIDOGREL IN THE TRITON-TIMI 38 TRIAL

E. Mahoney, S. Arnold, Y. Lei, 2008 .

Baseline fasting plasma insulin levels predict risk for major adverse cardiovascular events among patients with diabetes and high-risk vascular disease: Insights from the ACCELERATE trial

S. Kashyap, A. Lincoff, S. Nissen, 2019, Diabetes & vascular disease research.

Abstract 17400: Lipoprotein(a) is a Determinant of Residual Cardiovascular Risk in the Setting of Optimal LDL-C in Statin-Treated Patients With Atherosclerotic Cardiovascular Disease

S. Nissen, E. McErlean, S. Nicholls, 2017 .

Efficacy and Safety of Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib Administered as Monotherapy in Japanese Patients With Primary Hypercholesterolemia.

A. Kiyosue, T. Teramoto, J. Riesmeyer, 2017, Circulation journal : official journal of the Japanese Circulation Society.

Efficacy and Safety of the Cholesteryl Ester Transfer Protein Inhibitor Evacetrapib in Combination With Atorvastatin in Japanese Patients With Primary Hypercholesterolemia.

A. Kiyosue, T. Teramoto, J. Riesmeyer, 2017, Circulation journal : official journal of the Japanese Circulation Society.

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.

W. E. Sanabria, John A. Hamling, Ju Han Kim, 2019, Lancet.